deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT01691898

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (ROMULUS)

A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination With Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab and a Non-Randomized Phase Ib/II Evaluation of Polatuzumab Vedotin in Combination With Obinutuzumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Sponsor: Genentech, Inc.

Updated 17 times since 2017 Last updated: Feb 20, 2020 Started: Sep 27, 2012 Primary completion: Mar 8, 2017 Completion: Feb 7, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Diffuse Large B-Cell Lymphoma and Follicular Lymphoma and is currently completed. Genentech, Inc. leads this study, which shows 17 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Sep 2017 · 2 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~May 2018 · 5 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Mar 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

Show 12 earlier versions
  1. Sep 2019 — Mar 2020 [monthly]

    Completed PHASE1_PHASE2

  2. Jun 2019 — Sep 2019 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not RecruitingCompleted

  3. Feb 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Nov 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Dec 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Sep 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Jul 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: RecruitingActive Not Recruiting

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .